Acute Myeloid Leukemia Stem Cells-Updates and Controversies

Stephen S. Chung, Christopher Y. Park

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is a genetically heterogeneous disorder of the hematopoietic system marked by maturation arrest and proliferation of leukemic cells in the bone marrow. Although most patients can be induced into a remission with initial chemotherapy, the majority is destined to relapse, with most relapsed patients eventually succumbing to their disease. The reservoir for relapse has been postulated to be a pool of "leukemic stem cells" (LSC), which have the capability to self-renew, giving rise to both new LSCs and non-self renewing progeny to recapitulate the full phenotypic and functional diversity of the primary leukemia. It is thought that LSCs resist chemotherapy by multiple mechanisms including increased quiescence, the expression of multi-drug resistance pumps, and residence in a protective bone marrow (BM) microenvironment. To date, direct evidence that LSCs represent the chemo-resistant population in AML is limited, and much work remains to more fully characterize this largely conceptual cell type in the pathogenesis of treatment resistance and disease relapse.

Original languageEnglish (US)
Title of host publicationCancer Stem Cells
PublisherWiley-Blackwell
Pages143-160
Number of pages18
Volume9781118356166
ISBN (Electronic)9781118356203
ISBN (Print)9781118356166
DOIs
StatePublished - Apr 14 2014
Externally publishedYes

Fingerprint

Myeloid Progenitor Cells
Chemotherapy
Stem cells
Acute Myeloid Leukemia
Bone
Recurrence
Hematopoietic System
Drug Therapy
Disease Resistance
Multiple Drug Resistance
Pumps
Bone Marrow Cells
Leukemia
Stem Cells
Bone Marrow
Pharmaceutical Preparations
Population
Therapeutics

Keywords

  • Acute myeloid leukemia stem cells (LSCs)
  • Hematopoietic stem and progenitor cell (HSPC)
  • Hematopoietic stem cells (HSCs)

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Chung, S. S., & Park, C. Y. (2014). Acute Myeloid Leukemia Stem Cells-Updates and Controversies. In Cancer Stem Cells (Vol. 9781118356166, pp. 143-160). Wiley-Blackwell. https://doi.org/10.1002/9781118356203.ch11

Acute Myeloid Leukemia Stem Cells-Updates and Controversies. / Chung, Stephen S.; Park, Christopher Y.

Cancer Stem Cells. Vol. 9781118356166 Wiley-Blackwell, 2014. p. 143-160.

Research output: Chapter in Book/Report/Conference proceedingChapter

Chung, SS & Park, CY 2014, Acute Myeloid Leukemia Stem Cells-Updates and Controversies. in Cancer Stem Cells. vol. 9781118356166, Wiley-Blackwell, pp. 143-160. https://doi.org/10.1002/9781118356203.ch11
Chung SS, Park CY. Acute Myeloid Leukemia Stem Cells-Updates and Controversies. In Cancer Stem Cells. Vol. 9781118356166. Wiley-Blackwell. 2014. p. 143-160 https://doi.org/10.1002/9781118356203.ch11
Chung, Stephen S. ; Park, Christopher Y. / Acute Myeloid Leukemia Stem Cells-Updates and Controversies. Cancer Stem Cells. Vol. 9781118356166 Wiley-Blackwell, 2014. pp. 143-160
@inbook{1c9e86147135414f9a213d735a2fb4df,
title = "Acute Myeloid Leukemia Stem Cells-Updates and Controversies",
abstract = "Acute myeloid leukemia (AML) is a genetically heterogeneous disorder of the hematopoietic system marked by maturation arrest and proliferation of leukemic cells in the bone marrow. Although most patients can be induced into a remission with initial chemotherapy, the majority is destined to relapse, with most relapsed patients eventually succumbing to their disease. The reservoir for relapse has been postulated to be a pool of {"}leukemic stem cells{"} (LSC), which have the capability to self-renew, giving rise to both new LSCs and non-self renewing progeny to recapitulate the full phenotypic and functional diversity of the primary leukemia. It is thought that LSCs resist chemotherapy by multiple mechanisms including increased quiescence, the expression of multi-drug resistance pumps, and residence in a protective bone marrow (BM) microenvironment. To date, direct evidence that LSCs represent the chemo-resistant population in AML is limited, and much work remains to more fully characterize this largely conceptual cell type in the pathogenesis of treatment resistance and disease relapse.",
keywords = "Acute myeloid leukemia stem cells (LSCs), Hematopoietic stem and progenitor cell (HSPC), Hematopoietic stem cells (HSCs)",
author = "Chung, {Stephen S.} and Park, {Christopher Y.}",
year = "2014",
month = "4",
day = "14",
doi = "10.1002/9781118356203.ch11",
language = "English (US)",
isbn = "9781118356166",
volume = "9781118356166",
pages = "143--160",
booktitle = "Cancer Stem Cells",
publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Acute Myeloid Leukemia Stem Cells-Updates and Controversies

AU - Chung, Stephen S.

AU - Park, Christopher Y.

PY - 2014/4/14

Y1 - 2014/4/14

N2 - Acute myeloid leukemia (AML) is a genetically heterogeneous disorder of the hematopoietic system marked by maturation arrest and proliferation of leukemic cells in the bone marrow. Although most patients can be induced into a remission with initial chemotherapy, the majority is destined to relapse, with most relapsed patients eventually succumbing to their disease. The reservoir for relapse has been postulated to be a pool of "leukemic stem cells" (LSC), which have the capability to self-renew, giving rise to both new LSCs and non-self renewing progeny to recapitulate the full phenotypic and functional diversity of the primary leukemia. It is thought that LSCs resist chemotherapy by multiple mechanisms including increased quiescence, the expression of multi-drug resistance pumps, and residence in a protective bone marrow (BM) microenvironment. To date, direct evidence that LSCs represent the chemo-resistant population in AML is limited, and much work remains to more fully characterize this largely conceptual cell type in the pathogenesis of treatment resistance and disease relapse.

AB - Acute myeloid leukemia (AML) is a genetically heterogeneous disorder of the hematopoietic system marked by maturation arrest and proliferation of leukemic cells in the bone marrow. Although most patients can be induced into a remission with initial chemotherapy, the majority is destined to relapse, with most relapsed patients eventually succumbing to their disease. The reservoir for relapse has been postulated to be a pool of "leukemic stem cells" (LSC), which have the capability to self-renew, giving rise to both new LSCs and non-self renewing progeny to recapitulate the full phenotypic and functional diversity of the primary leukemia. It is thought that LSCs resist chemotherapy by multiple mechanisms including increased quiescence, the expression of multi-drug resistance pumps, and residence in a protective bone marrow (BM) microenvironment. To date, direct evidence that LSCs represent the chemo-resistant population in AML is limited, and much work remains to more fully characterize this largely conceptual cell type in the pathogenesis of treatment resistance and disease relapse.

KW - Acute myeloid leukemia stem cells (LSCs)

KW - Hematopoietic stem and progenitor cell (HSPC)

KW - Hematopoietic stem cells (HSCs)

UR - http://www.scopus.com/inward/record.url?scp=84926454312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926454312&partnerID=8YFLogxK

U2 - 10.1002/9781118356203.ch11

DO - 10.1002/9781118356203.ch11

M3 - Chapter

AN - SCOPUS:84926454312

SN - 9781118356166

VL - 9781118356166

SP - 143

EP - 160

BT - Cancer Stem Cells

PB - Wiley-Blackwell

ER -